The 2021 WHO classification of central nervous system tumors: what neurologists need to know.
The 2021 WHO classification of central nervous system tumors: what neurologists need to know.
复制标题
DOI：
10.1097/wco.0000000000001109
复制
发表时间：
2022-12-01
影响因子：
4.8
通讯作者：
中科院分区：
文献类型：
--
作者：
The recently published 5th Edition of the World Health Organization classification of tumors of the central nervous system (WHO CNS-5) introduces substantial clinically relevant changes due to improved understanding of the molecular underpinnings of brain tumor types as biological entities. This review highlights pertinent changes for practicing neurologists. Diffuse gliomas are now divided into adult- and pediatric-types. Adult-types are greatly simplified, being classified into three groups based on IDH and 1p/19q status, with molecular grading criteria now included. Pediatric-types are divided into low- or high-grade and further classified based on molecular features corresponding to clinical behavior. While still recognizing previous morphological subtypes, meningioma is now a single tumor type, with greatly advanced correlations between molecular alterations, locations, morphologic subtypes and grades. For the first time, ependymomas are classified based on integration of anatomical location, histopathology and molecular alterations. Importantly, WHO CNS-5 includes a number of new tumor types that have similar clinicopathologic features and are grouped together by their distinctive molecular characteristics. The classification of CNS tumors according to objective, reproducible molecular genetic alterations provides greater opportunity for neurologists to offer individualized treatment options, enroll homogenous patient populations into clinical trials, and ultimately discover novel therapeutics.
